Generalized Pustular Psoriasis (GPP) Market

Generalized Pustular Psoriasis (GPP) Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

215

Base Year:

2023

Nov - 2024

Format:

Report Code:

VMR-3179

Segments Covered

By Treatment Topical Agents, Non-biologic agents, Biologic agents, TNFa antagonists, Antibiotics, Others
By Route of Administration Oral, Topical, Subcutaneous, Other
By End User Hospitals, Dermatology Clinics, Specialty Centers, Others
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2023
Forecast Years:	2024 - 2032
Historical Years:	2018 - 2022
Revenue 2023:	USD 18.3 Billion
Revenue 2032:	USD 31.73 Billion
Revenue CAGR (2024 - 2032):	6.3%
Fastest Growing Region (2024 - 2032)	Asia Pacific
Largest Region (2023):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Generalized Pustular Psoriasis (GPP) Market - Segment Analysis
1. Overview
2. Global Generalized Pustular Psoriasis (GPP) Market, 2016 - 2028 (USD Million)
3. Global Generalized Pustular Psoriasis (GPP) Market - by Treatment
  1. By Topical Agents
  2. By Non-biologic agents
  3. By Biologic agents
  4. By TNFa antagonists
  5. By Antibiotics
  6. By Others
4. Global Generalized Pustular Psoriasis (GPP) Market - by Route of Administration
  1. By Oral
  2. By Topical
  3. By Subcutaneous
  4. By Other
5. Global Generalized Pustular Psoriasis (GPP) Market - by End User
  1. By Hospitals
  2. By Dermatology Clinics
  3. By Specialty Centers
  4. By Others
6. Global Generalized Pustular Psoriasis (GPP) Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
7. Market comparative analysis
North America Generalized Pustular Psoriasis (GPP) Market - Segment Analysis
1. Overview
2. North America Generalized Pustular Psoriasis (GPP) Market, 2016 - 2028 (USD Million)
3. North America Generalized Pustular Psoriasis (GPP) Market, by Treatment
  1. By Topical Agents
  2. By Non-biologic agents
  3. By Biologic agents
  4. By TNFa antagonists
  5. By Antibiotics
  6. By Others
4. North America Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
  1. By Oral
  2. By Topical
  3. By Subcutaneous
  4. By Other
5. North America Generalized Pustular Psoriasis (GPP) Market, by End User
  1. By Hospitals
  2. By Dermatology Clinics
  3. By Specialty Centers
  4. By Others
6. North America Generalized Pustular Psoriasis (GPP) Market, by Country
  1. U.S.
    1. U.S. Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. U.S. Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. U.S. Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  2. Canada
    1. Canada Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Canada Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Canada Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  3. Mexico
    1. Mexico Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Mexico Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Mexico Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
Europe Generalized Pustular Psoriasis (GPP) Market - Segment Analysis
1. Overview
2. Europe Generalized Pustular Psoriasis (GPP) Market, 2016 - 2028 (USD Million)
3. Europe Generalized Pustular Psoriasis (GPP) Market, by Treatment
  1. By Topical Agents
  2. By Non-biologic agents
  3. By Biologic agents
  4. By TNFa antagonists
  5. By Antibiotics
  6. By Others
4. Europe Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
  1. By Oral
  2. By Topical
  3. By Subcutaneous
  4. By Other
5. Europe Generalized Pustular Psoriasis (GPP) Market, by End User
  1. By Hospitals
  2. By Dermatology Clinics
  3. By Specialty Centers
  4. By Others
6. Europe Generalized Pustular Psoriasis (GPP) Market, by Country
  1. Germany
    1. Germany Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Germany Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Germany Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  2. UK
    1. UK Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. UK Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. UK Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  3. France
    1. France Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. France Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. France Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  4. Spain
    1. Spain Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Spain Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Spain Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  5. Italy
    1. Italy Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Italy Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Italy Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  6. BENELUX
    1. BENELUX Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. BENELUX Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. BENELUX Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  7. Rest of Europe
    1. Rest Of Europe Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Rest Of Europe Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Rest Of Europe Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
Asia Pacific Generalized Pustular Psoriasis (GPP) Market - Segment Analysis
1. Overview
2. Asia Pacific Generalized Pustular Psoriasis (GPP) Market, 2016 - 2028 (USD Million)
3. Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Treatment
  1. By Topical Agents
  2. By Non-biologic agents
  3. By Biologic agents
  4. By TNFa antagonists
  5. By Antibiotics
  6. By Others
4. Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
  1. By Oral
  2. By Topical
  3. By Subcutaneous
  4. By Other
5. Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by End User
  1. By Hospitals
  2. By Dermatology Clinics
  3. By Specialty Centers
  4. By Others
6. Asia Pacific Generalized Pustular Psoriasis (GPP) Market, by Country
  1. China
    1. China Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. China Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. China Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  2. Japan
    1. Japan Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Japan Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Japan Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  3. India
    1. India Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. India Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. India Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  4. South Korea
    1. South Korea Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. South Korea Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. South Korea Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  5. South East Asia
    1. South East Asia Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. South East Asia Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. South East Asia Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Rest of Asia Pacific Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Rest of Asia Pacific Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
Latin America Generalized Pustular Psoriasis (GPP) Market - Segment Analysis
1. Overview
2. Latin America Generalized Pustular Psoriasis (GPP) Market, 2016 - 2028 (USD Million)
3. Latin America Generalized Pustular Psoriasis (GPP) Market, by Treatment
  1. By Topical Agents
  2. By Non-biologic agents
  3. By Biologic agents
  4. By TNFa antagonists
  5. By Antibiotics
  6. By Others
4. Latin America Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
  1. By Oral
  2. By Topical
  3. By Subcutaneous
  4. By Other
5. Latin America Generalized Pustular Psoriasis (GPP) Market, by End User
  1. By Hospitals
  2. By Dermatology Clinics
  3. By Specialty Centers
  4. By Others
6. Latin America Generalized Pustular Psoriasis (GPP) Market, by Country
  1. Brazil
    1. Brazil Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Brazil Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Brazil Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  2. Argentina
    1. Argentina Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Argentina Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Argentina Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  3. Rest of Latin America
    1. Rest of Latin America Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Rest of Latin America Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Rest of Latin America Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
Middle East & Africa Generalized Pustular Psoriasis (GPP) Market - Segment Analysis
1. Overview
2. Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Treatment
  1. By Topical Agents
  2. By Non-biologic agents
  3. By Biologic agents
  4. By TNFa antagonists
  5. By Antibiotics
  6. By Others
4. Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Route of Administration
  1. By Oral
  2. By Topical
  3. By Subcutaneous
  4. By Other
5. Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by End User
  1. By Hospitals
  2. By Dermatology Clinics
  3. By Specialty Centers
  4. By Others
6. Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, by Country
  1. GCC Countries
    1. GCC Countries Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. GCC Countries Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. GCC Countries Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  2. South Africa
    1. South Africa Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. South Africa Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. South Africa Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, By Treatment
      1. By Topical Agents
      2. By Non-biologic agents
      3. By Biologic agents
      4. By TNFa antagonists
      5. By Antibiotics
      6. By Others
    2. Rest of Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, By Route of Administration
      1. By Oral
      2. By Topical
      3. By Subcutaneous
      4. By Other
    3. Rest of Middle East & Africa Generalized Pustular Psoriasis (GPP) Market, By End User
      1. By Hospitals
      2. By Dermatology Clinics
      3. By Specialty Centers
      4. By Others
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. Eli Lilly and Company
2. Amgen Inc.
3. Johnson & Johnson
4. AstraZeneca
5. Bristol Myers Squibb
6. UCB Inc.
7. Pfizer Inc.
8. AbbVie Inc.
9. Novartis AG
10. Astellas Pharma Inc.
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

FAQ

Frequently Asked Question

What is the global demand for Generalized Pustular Psoriasis (GPP) in terms of revenue?

The global Generalized Pustular Psoriasis (GPP) valued at USD 18.3 Billion in 2023 and is expected to reach USD 31.73 Billion in 2032 growing at a CAGR of 6.3%.

Which are the prominent players in the market?

The prominent players in the market are Eli Lilly and Company, Amgen Inc., Johnson & Johnson, AstraZeneca, Bristol Myers Squibb, UCB Inc., Pfizer Inc., AbbVie Inc., Novartis AG, Astellas Pharma Inc..

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 6.3% between 2024 and 2032.

What are the driving factors fueling the growth of the market.

The driving factors of the Generalized Pustular Psoriasis (GPP) include

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Generalized Pustular Psoriasis (GPP) in 2023.

Generalized Pustular Psoriasis (GPP) Market

Generalized Pustular Psoriasis (GPP) Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Generalized Pustular Psoriasis (GPP) in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Quick Links

For Buying Inquiry

Generalized Pustular Psoriasis (GPP) Market

Generalized Pustular Psoriasis (GPP) Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Generalized Pustular Psoriasis (GPP) in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Generalized Pustular Psoriasis (GPP) Market

Vantage Point Interactive Dashboard